Edelweiss Mutual Fund · #148555
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Direct Plan - Growth
Other · Index Funds · Direct · Growth
Direct TER: 0.55% · as of
5-year NAV · change the window using the controls in the rolling-returns card below ↓
2021-10-25 → 2026-10-21
Latest NAV
₹23.8610
as of 2026-10-21 · +0.33% vs 2026-10-19
Earliest NAV in archive
2020-11-02
AMFI archive begins Apr 2006
Trailing CAGR vs assigned benchmark
| Window | Scheme CAGR | Benchmark CAGR | Excess | Period |
|---|---|---|---|---|
| 1y | +13.06% | -12.41%* | +25.48% | 2025-10-23 → today · 1.0y |
| 3y | +19.36% | +5.58%* | +13.78% | 2023-10-23 → today · 3.0y |
| 5y | +13.88% | — | — | 2021-10-22 → today · 5.0y |
Benchmark assignment is mapped by category and sub-category from public sources.
* The total-return version of this benchmark is no longer published,
so starred rows use its price index, which excludes dividends. That understates the benchmark by roughly its
dividend yield (about 1.2% a year) and overstates Excess by the same.
"Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).
Rolling 1-year returns distribution · 1181 daily entry points · last 5 years
Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.
Median 1y return
+13.3%
Mean 1y return
+14.9%
Best / worst 1y
+49.8% / -10.4%
Windows positive
81%
Longer rolling windows · annualised
Same idea over longer holding periods. Returns are CAGR (annualised) so they're directly comparable to the trailing-CAGR table above.
| Period | Median | Mean | Worst | Best | % positive | Windows |
|---|---|---|---|---|---|---|
| 3y rolling | +17.6% | +17.5% | +11.4% | +23.7% | 100% | 705 |
| 5y rolling | +13.8% | +14.0% | +12.3% | +15.9% | 100% | 231 |
Beat-benchmark consistency · vs assigned benchmark, across overlapping windows
Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.
| Period | Windows beat | Total windows | % beat | Avg excess (annualised) |
|---|---|---|---|---|
| 1y rolling | 585 | 1107 | 53% | +1.7% |
| 3y rolling | 487 | 631 | 77% | +3.1% |
| 5y rolling | 105 | 157 | 67% | +1.4% |
Windows ending up to 02 Jul 2026, the benchmark's last published value.
Monthly returns · since inception (Nov 2020)
How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.3 | +5.5 | -4.5 | +2.5 | +3.7 | +5.8 | +3.7 | +2.5 | -3.5 | -1.8 | · | · | +11.3 |
| 2025 | -3.7 | -3.0 | +2.8 | +1.0 | -2.1 | +3.5 | +2.2 | -1.4 | -0.2 | +3.5 | +4.9 | -1.7 | +5.5 |
| 2024 | +6.7 | +3.4 | +1.2 | -1.0 | -0.2 | +5.4 | +6.3 | +6.1 | +0.6 | -2.4 | -2.0 | +2.7 | +29.6 |
| 2023 | -2.7 | -4.4 | +2.0 | +4.5 | +1.4 | +7.3 | +5.4 | +0.6 | +0.9 | -4.6 | +9.3 | +3.7 | +25.1 |
| 2022 | -7.6 | -1.6 | +4.7 | -1.2 | -4.3 | -2.9 | +5.2 | -1.2 | +0.6 | +5.1 | +1.6 | -2.4 | -4.8 |
| 2021 | -3.3 | -1.1 | +3.1 | +7.5 | +2.0 | +4.7 | +2.2 | +2.3 | -3.2 | -1.4 | +1.8 | +3.2 | +18.8 |
| 2020 | · | · | · | · | · | · | · | · | · | · | · | +5.6 | +5.6 |
| Avg | -2.1 | -0.2 | +1.6 | +2.2 | +0.1 | +4.0 | +4.2 | +1.5 | -0.8 | +0.1 | +3.1 | +1.8 | +14.8 |
All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (5 complete calendar years in the last column); the running month is left out of it.
Portfolio mix · asset class breakdown as of 2026-03-31
Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings
Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).
- Large Cap 44.6%
- Mid Cap 51.2%
- Small Cap 4.2%
Index overlap
· vs · share of this fund's AUM that sits in stocks the index also includes32.2%
5 of 25 holdings are index members
Mostly stocks outside the benchmark universe
As of 2026-03-31
How to read this: This number shows whether the fund invests in the same stocks as the index. It does not show whether the fund weights those stocks like the index. A low number (say below 60%) means the fund holds a meaningful share in stocks the index doesn't carry at all (typical of sectoral, small-cap-tilted or international funds vs a broad benchmark). A high number (80%+) is normal for any large-cap or flexi-cap fund, because Indian active funds mostly pick from the same large and mid-cap stocks as the Nifty 500. It does not on its own signal a closet index fund; to identify that you'd need per-stock weight comparison, which requires index constituent weights we don't currently ingest.
Top stocks held · 25 holdings as of 2026-03-31 See changes vs previous snapshot →
| Stock | Sector | % of fund |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | 11.73% |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.59% |
| Max Healthcare Institute Limited | Healthcare | 5.30% |
| Divi's Laboratories Limited | Healthcare | 5.08% |
| Cipla Limited | Healthcare | 4.84% |
| Dr. Reddy's Laboratories Limited | Healthcare | 4.76% |
| Lupin Limited | Healthcare | 4.13% |
| Torrent Pharmaceuticals Limited | Healthcare | 3.55% |
| Fortis Healthcare Limited | Healthcare | 2.77% |
| Laurus Labs Limited | Healthcare | 2.44% |
| Aurobindo Pharma Limited | Healthcare | 2.37% |
| Glenmark Pharmaceuticals Limited | Healthcare | 2.27% |
| Alkem Laboratories Limited | Healthcare | 1.79% |
| Mankind Pharma Limited | Healthcare | 1.72% |
| Biocon Limited | Healthcare | 1.55% |
| IPCA Laboratories Limited | Healthcare | 1.53% |
| Zydus Lifesciences Limited | Healthcare | 1.23% |
| JB Chemicals & Pharmaceuticals Limited | Healthcare | 1.19% |
| Aster DM Healthcare Limited | Healthcare | 1.05% |
| Ajanta Pharma Limited | Healthcare | 0.89% |
Sector mix
- Healthcare 100.0%
Risk metrics, trailing 3y (633 matched daily returns, 2023-10-25 → 2026-07-02)
Calmar
+1.59
CAGR / |max DD| in window
Risk-free rate assumed 6.0% annualised. Benchmark = Nifty 50 TRI (assigned by category mapping).
Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.